WELCOME TO SAGEbioExtending healthy life years

Modular biologics to precisely target and resolve chronic inflammation

https://sagebio.tech/wp-content/uploads/2020/06/home_hero_detail.jpg

ABOUT USSAGEbio is developing a new class of modular biologics to precisely control chronic inflammation

Our modular Synbodies are engineered single-domain synthetic antibodies fused via adaptable linkers to a pharmacokinetics controlling domain. This design combines the specificity of biologics with the flexibility and scalability of synthetic scaffolds.

SAGEbio’s modular Synbodies precisely control chronic inflammation, a key driver of many high-burden, non-communicable diseases.

Our platform integrates AI-supported discovery, an in-house single-domain antibody library, and a plug-and-play Synbody architecture to rapidly move from target concept to advanced preclinical candidates. It enables rapid design and scalable production of highly specific immunomodulators with tunable pharmacokinetics, superior tissue penetration, and strong developability.

Focused on chronic inflammation and immune-mediated diseases
Modular Synbody platform for rapid design, assembly, and scale-up
Lead program: anti-TL1A Synbody targeting the TL1A:DR3 axis

Broad Expertise in Modular Immunotherapy

TECHNOLOGYSynbody Design & Discovery

We leverage AI-guided sequence design an in-house single-domain antibody library, and rapid in vitro screening. This allows us to efficiently discover and refine Synbodies against key inflammatory targets, including cytokines and their receptors with optimized biophysical properties.

PHARMACOLOGYPharmacokinetic Tuning

Our Synbodies include optimized pharmacokinetics controlling domain, allowing control of pharmacokinetic properties. This design enables tunable half-life and exposure, controls effector function as needed per indication, and maintains manufacturability via established production infrastructure.

TRANSLATIONAL IMMUNOLOGYPreclinical De-risking

We evaluate Synbodies in relevant in vitro and in vivo models to link target engagement to pathway modulation and disease-relevant outcomes. Our translational strategy is focused on generating clear, mechanistic data that supports differentiation versus existing therapies and informs clinical design.

TARGETING IBD AND FIBROTIC DISEASEAnti-TL1A Synbody

SAGEbio’s lead program is an anti-TL1A Synbody designed to selectively block the TL1A:DR3 interaction while aiming to preserve broader immune function. TL1A is a central amplifier of chronic inflammation. Our Synbody is intended to deliver precise pathway inhibition exceeding existing therapies.

Intentional Innovation

BUILDING PARTNERSHIPSSAGEbio is built to collaborate. We work with leading academic centers, pharma, and biotech to accelerate our Synbody programs toward the clinic and unlock the full value of our platform. Our modular, human-compatible Synbody format, combined with a cross-disciplinary team in immunology, protein engineering, and AI-assisted design, makes our platform ideally suited for:

Asset Co-Development

Designing and advancing Synbodies against partner-selected inflammatory or fibrotic targets.

Asset-centric Deals

Structuring indication- or territory-specific partnerships around our anti-TL1A Synbody and TL1A/DR3-pathway assets.

Platform Collaborations

Running multi-asset discovery campaigns to generate Synbodies across a partner’s cytokine or receptor portfolio.

Discovery Initiatives

Leveraging our Synbody platform and expert team to explore emerging cytokine pathways and rapidly advance first-in-class biologics together.